One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Soligenix, Inc.
SNGX · NCM · Healthcare · Biotechnology
Current price
$0.38
52-week range
$0.28 - $1.97
Market cap
$8.36M
Balance sheet
Healthy
-55.36x Concerning
Net cash $9.51M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
2 Risks
0 rewards · 2 risks
- Risk Return on equity was -241.7% last year — the company lost money on shareholders' equity.
- Risk Insider ownership is only 4.6% (peer median: 6.3%).
What this company does
Soligenix, Inc.
Soligenix is a healthcare company working to get new treatments approved for rare conditions, like a specific type of skin cancer, and to create vaccines for public health threats. It currently earns no money from selling products, as its treatments are all still in clinical trials (the required testing process to prove a drug is safe and works). Therefore, the company's success and ability to make a profit depend entirely on whether these drugs in development are eventually approved for sale by health authorities.
How the company got here
Soligenix was founded in 1987 and has since focused on developing medicines for diseases that have few or no effective treatments. Originally named DOR BioPharma, the company changed its name to Soligenix in 2009. Over the years, it has concentrated its efforts on becoming a 'late-stage' company, which means its most promising potential products are in the final phases of testing before they can be considered for approval by health regulators.
What it actually does
Soligenix is a biopharmaceutical company that works to create and sell treatments for rare diseases. Think of them as scientists and researchers trying to solve medical puzzles that larger companies might overlook. They don't sell everyday drugs; instead, they focus on serious conditions with 'unmet medical needs,' meaning patients are still waiting for a good solution. Their work involves years of research and rigorous testing, known as clinical trials, to prove a potential medicine is safe and effective.
Specialized BioTherapeutics
This is the company's main division, focused on developing treatments for rare diseases that affect small numbers of people. Its leading candidate is a therapy called HyBryte™, a gel applied to the skin and activated by a special light to treat a rare type of skin cancer called cutaneous T-cell lymphoma. This segment is the core of the business, where they hope to get their first major product approved for sale after completing the final and most important stage of testing, called a Phase 3 clinical trial (the last step before asking for government approval to sell a new drug).
Public Health Solutions
This part of the company develops vaccines and treatments for broader health threats, often with government support. For example, they are working on a vaccine called RiVax® to protect against poisoning from the toxin ricin, which is considered a biodefense threat. This segment also includes work on vaccines for infectious diseases like Ebola and Marburg. A key piece of their technology here is ThermoVax®, a method to make vaccines stable at warmer temperatures, which would make them easier to store and transport. This business line is largely funded by government grants and contracts rather than product sales.
What management is betting on now
The company's main focus is on successfully completing the final testing for its skin cancer therapy, HyBryte™, with results expected in the second half of 2026. Getting this drug approved by regulators is their top priority, as it would be their first major product to reach the market and generate significant revenue. Management is also advancing other potential treatments for inflammatory diseases. They have also stated they are exploring strategic options, which could mean finding a partner company to help with costs or even a potential sale of the company, to best position their products for success.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2025 Q2
$-2.75M
FY2025 Q3
$-2.93M
FY2025 Q4
$-2.75M
Revenue
—
Net income
$-1.99M
Diluted EPS
-0.12
Operating cash flow
$-1.71M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-2.82M
Diluted EPS
-0.28
Operating cash flow
$-2.36M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-2.61M
Diluted EPS
0.32
Operating cash flow
$-2.75M
Free cash flow
$-2.75M
Fetching…
Sources
Revenue
—
Net income
$-2.53M
Diluted EPS
-0.58
Operating cash flow
$-2.93M
Free cash flow
$-2.93M
Fetching…
Sources
Revenue
—
Net income
$-2.70M
Diluted EPS
-0.82
Operating cash flow
$-2.74M
Free cash flow
$-2.75M
Fetching…
Sources
Revenue
—
Net income
$-3.24M
Diluted EPS
-1.06
Operating cash flow
$-1.85M
Free cash flow
—
Fetching…
Sources
Revenue
$-2.34K
Net income
$-2.99M
Diluted EPS
-2.71
Operating cash flow
$-2.23M
Free cash flow
—
Fetching…
Sources
Revenue
$2.34K
Net income
$-1.72M
Diluted EPS
-0.78
Operating cash flow
$-2.91M
Free cash flow
—
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $0.38
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $9.5M - more cash than debt. Interest coverage -55.4x.
Net debt
$-9.51M
Interest coverage
-55.36x
Soligenix, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 3 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
SNGX
BASELINE
Soligenix, Inc.
Total debt $302.59K Interest coverage -55.36x This is the baseline the peer rows are being compared against.
Total debt $19.87M Interest coverage -23.92x Neither company has much profit cushion over interest right now.
Total debt $205.66K Interest coverage -5.59x Neither company has much profit cushion over interest right now.
Total debt $36.02M Interest coverage -57.76x Neither company has much profit cushion over interest right now.
What you should know
The case for and against SNGX
0 Rewards
2 Risks
Rewards
Risks
-
Return on equity was -241.7% last year — the company lost money on shareholders' equity.
-
Insider ownership is only 4.6% (peer median: 6.3%).
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-1.54x
P/B
1.25x
P/S
—
EV/EBITDA
0.10x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-241.7%
ROA
-84.9%
Health
Liquidity and balance-sheet strength
Debt / equity
0.05x
Current ratio
2.77x
Quick ratio
2.67x
Total debt
$302.59K
Total cash
$9.81M
Growth
How the business has been compounding
Revenue TTM
$119.37K
Revenue 5Y CAGR
-38.3%
EPS TTM
-0.72
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-9.74M
Free CF TTM
$-10.27M
FCF margin
-8,605.5%
Dividend
Shareholder payout
Yield
—
Payout ratio
0.0%
Last ex-div date
—